• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.

作者信息

King Daniel A, Smith Amber R, Pineda Gino, Nakano Michitaka, Michelini Flavia, Goedegebuure S Peter, Thyparambil Sheeno, Liao Wei-Li, McCormick Aaron, Ju Jihang, Cioffi Michele, Zhang Xiuli, Hundal Jasreet, Griffith Malachi, Grandori Carla, Pollastro Maddy, Rosati Rachele, Margossian Astrid, Chatterjee Payel, Ainge Trevor, Flory Marta, Ocampo Paolo, Chen Lee-May, Poultsides George A, Baron Ari D, Chang Daniel T, Herman Joseph M, Gillanders William E, Park Haeseong, Hoos William A, Nichols Mike, Fisher George A, Kuo Calvin J

机构信息

Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY.

Xilis Corporation, Durham, NC.

出版信息

JCO Precis Oncol. 2023 Apr;7:e2100489. doi: 10.1200/PO.21.00489.

DOI:10.1200/PO.21.00489
PMID:37079860
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10309581/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/05c2d065c086/po-7-e2100489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/d1d04a739c81/po-7-e2100489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/830fcd682f83/po-7-e2100489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/ddbe79ab6852/po-7-e2100489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/05c2d065c086/po-7-e2100489-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/d1d04a739c81/po-7-e2100489-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/830fcd682f83/po-7-e2100489-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/ddbe79ab6852/po-7-e2100489-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f927/10309581/05c2d065c086/po-7-e2100489-g005.jpg

相似文献

1
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.精准免疫和靶向治疗后广泛转移的人表皮生长因子受体2扩增胰腺癌完全缓解，并描述测序及类器官相关性
JCO Precis Oncol. 2023 Apr;7:e2100489. doi: 10.1200/PO.21.00489.
2
Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.转移性胰腺腺癌的当前标准与新型治疗选择
Oncology (Williston Park). 2015 Nov;29(11):809-20, 886.
3
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.胰腺导管腺癌的药物治疗管理：当前与新兴概念
Drugs Aging. 2017 May;34(5):331-357. doi: 10.1007/s40266-017-0453-y.
4
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.携带BRCA2和CHEK2基因双杂合种系突变的转移性胰腺癌对化疗的完全缓解——病例报告
Klin Onkol. 2020 Spring;33(3):220-225. doi: 10.14735/amko2020220.
5
Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.表皮生长因子受体（EGFR）与人类表皮生长因子受体-2（HER-2）在胰腺导管腺癌中的共表达：一项使用免疫组织化学并与荧光原位杂交基因扩增相关联的对比研究。
Oncol Rep. 2007 Jul;18(1):151-5.
6
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.曲妥珠单抗联合卡培他滨治疗人表皮生长因子受体 2 过表达转移性胰腺肿瘤的多中心 II 期临床试验。
Br J Cancer. 2012 Mar 13;106(6):1033-8. doi: 10.1038/bjc.2012.18. Epub 2012 Feb 28.
7
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.BRCA2 基因突变携带者转移性胰腺腺癌患者接受顺铂为基础的治疗后达到完全缓解。
Cancer Biol Ther. 2011 Aug 1;12(3):165-8. doi: 10.4161/cbt.12.3.16292.
8
Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles.表皮生长因子受体及其在纳米颗粒介导的胰腺癌治疗中的作用。
Int J Nanomedicine. 2019 Dec 9;14:9693-9706. doi: 10.2147/IJN.S226628. eCollection 2019.
9
Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.用于胰腺腺癌个体化治疗的化疗耐药和化疗敏感的生物标志物和途径。
Pharmacogenomics. 2019 Jan;20(2):113-127. doi: 10.2217/pgs-2018-0073. Epub 2018 Dec 12.
10
HER-family gene amplification and expression in resected pancreatic cancer.HER家族基因在切除的胰腺癌中的扩增与表达。
Eur J Surg Oncol. 2009 Oct;35(10):1098-104. doi: 10.1016/j.ejso.2009.02.013. Epub 2009 Mar 21.

引用本文的文献

1
Precision Medicine: IL-1RA and Pancreatic Cancer Organoids.精准医学：白细胞介素-1受体拮抗剂与胰腺癌类器官
Biology (Basel). 2025 May 25;14(6):604. doi: 10.3390/biology14060604.
2
Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma.用于胰腺导管腺癌诊断和预后评估的分子生物标志物
J Pers Med. 2025 Jun 5;15(6):236. doi: 10.3390/jpm15060236.
3
Establishment and characterization of novel patient-derived esophageal tumoroids with long-term cultivability.具有长期可培养性的新型患者来源食管类肿瘤的建立与表征

本文引用的文献

1
Immune organoids: from tumor modeling to precision oncology.免疫类器官：从肿瘤建模到精准肿瘤学。
Trends Cancer. 2022 Oct;8(10):870-880. doi: 10.1016/j.trecan.2022.06.001. Epub 2022 Jun 27.
2
Tumor organoids: Opportunities and challenges to guide precision medicine.肿瘤类器官：精准医学的机遇与挑战
Cancer Cell. 2021 Sep 13;39(9):1190-1201. doi: 10.1016/j.ccell.2021.07.020. Epub 2021 Aug 19.
3
An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer.一种用于剖析癌症中对 PD-1 阻断反应的离体肿瘤片段平台。
Hum Cell. 2025 Mar 19;38(3):72. doi: 10.1007/s13577-025-01206-x.
4
Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.全球个性化癌症医学创新网络（WIN）联盟：为患者带来下一代精准肿瘤学。
Oncotarget. 2025 Mar 12;16:140-162. doi: 10.18632/oncotarget.28703.
5
Theranostic nanoparticles for detection and treatment of pancreatic cancer.用于胰腺癌检测与治疗的诊疗纳米颗粒。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024 Jul-Aug;16(4):e1983. doi: 10.1002/wnan.1983.
6
Quantitative proteomic analysis of HER2 protein expression in PDAC tumors.胰腺癌肿瘤中HER2蛋白表达的定量蛋白质组学分析。
Clin Proteomics. 2024 Mar 20;21(1):24. doi: 10.1186/s12014-024-09476-7.
7
(HER2) amplifications and co-occurring alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition.胰腺导管腺癌患者循环游离DNA中的（人表皮生长因子受体2）扩增及共现改变与对人表皮生长因子受体2抑制的反应
Front Oncol. 2024 Feb 8;14:1339302. doi: 10.3389/fonc.2024.1339302. eCollection 2024.
8
The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.趋化因子在协调针对胰腺导管腺癌的免疫反应中的作用
Cancers (Basel). 2024 Jan 28;16(3):559. doi: 10.3390/cancers16030559.
9
Case report: tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma.病例报告：肿瘤类器官药物测试确定了IV期卵巢癌的治疗选择。
Front Oncol. 2024 Jan 4;13:1267650. doi: 10.3389/fonc.2023.1267650. eCollection 2023.
Nat Med. 2021 Jul;27(7):1250-1261. doi: 10.1038/s41591-021-01398-3. Epub 2021 Jul 8.
4
Applications of Organoids for Cancer Biology and Precision Medicine.类器官在癌症生物学和精准医学中的应用。
Nat Cancer. 2020 Aug;1(8):761-773. doi: 10.1038/s43018-020-0102-y. Epub 2020 Aug 18.
5
Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?在HER2阳性乳腺癌中，HER2基因扩增水平与曲妥珠单抗联合化疗新辅助治疗的反应之间是否存在相关性？
Virchows Arch. 2021 Oct;479(4):853-857. doi: 10.1007/s00428-021-03104-7. Epub 2021 May 1.
6
Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.基于类器官药物反应的结直肠癌患者前瞻性实验治疗。
ESMO Open. 2021 Jun;6(3):100103. doi: 10.1016/j.esmoop.2021.100103. Epub 2021 Apr 19.
7
Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation.优化的多表位新抗原 DNA 疫苗在临床前模型和临床转化中引发新抗原特异性免疫反应。
Genome Med. 2021 Apr 21;13(1):56. doi: 10.1186/s13073-021-00872-4.
8
Patient-Derived Cancer Organoids as Predictors of Treatment Response.患者来源的癌症类器官作为治疗反应的预测指标
Front Oncol. 2021 Mar 18;11:641980. doi: 10.3389/fonc.2021.641980. eCollection 2021.
9
Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy.消融放疗重编程胰腺肿瘤微环境有利于免疫检查点阻断治疗。
Int J Mol Sci. 2021 Feb 19;22(4):2091. doi: 10.3390/ijms22042091.
10
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).评估吉西他滨、曲妥珠单抗和厄洛替尼联合作为转移性胰腺腺癌（GATE 1）一线治疗的Ⅱ期研究。
Int J Cancer. 2021 Feb 1;148(3):682-691. doi: 10.1002/ijc.33225. Epub 2020 Sep 2.